Notice of Clarifications for PAR-16-357 "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1)"

Notice Number: NOT-DA-16-047

Key Dates
Release Date:  October 14, 2016

Related Announcements
PAR-16-357

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to clarify submission instructions in the PAR-16-357 "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1)" required for application submission.

Part 2. Section II. Award Information

Currently reads:


Application Types Allowed

New 
Resubmission
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

Resubmission applications are not allowed for DP1s and cannot pass validations. Therefore this text is modified to read:


Application Types Allowed

New 

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

Part 2. Section IV.2 Content and Form of Application Submission

SF424(R&R) Senior/Key Person Profile

Currently reads:
All instructions in the SF424 (R&R) Application Guide must be followed.

Modified to read:
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

The Project Director/Principal Investigator (PD/PI) is the only individual who can be listed on the form.

Current & Pending Support: Required attachment.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1309 
Email: jpollock@mail.nih.gov